Enoxaparin Sodium Injection, USP is used to treat prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or patients who have limited mobility during severe illness.
Lovenox’s annual sales in the United States were approximately $1.8 billion as of November 2014, according to data from IMS Health.
Recently, Teva also launched the generic Zyvox (linezolid) Injection, used to treat infections that are caused by Gram-positive bacteria.
“Teva is committed and focused on building a stronger generic injectable business globally,” Siggi Olafsson, president and CEO of Teva Global Generic Medicines, said. “With the launch of Enoxaparin Sodium Injection, USP and Linezolid Injection, accompanied by the reintroduction of three generic injectable products, we are leveraging the strength of our internal and external resources to deliver the right portfolio as part of our growth strategy. As the No. 1 generics company in the world, we can quickly bring a range of high-quality, cost-effective generic injectable treatments to patients within the doctor’s office, hospital, or clinic.”
Teva was founded on 1985. In the U.S., the company is part of Teva Pharmaceutical Industries Ltd.
Alerts Sign-up